Loading...
NPI 1356006407 · Lombard, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Us Spa Corp is a clinical medical laboratory provider located in Lombard, Illinois. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Us Spa Corp |
| Address | 920 N Ridge Ave Ste A4 |
| City | Lombard |
| State | IL |
| ZIP | 60148 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 3, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $20.4M |
| Medicaid | $384.3K |
US SPA CORP’s Medicare business is overwhelmingly concentrated in a single code: K1034 generates $20.9M and accounts for 100.0% of the provider’s total Medicare revenue, indicating the organization’s Medicare activity is effectively limited to provision of nonprescription self-administered COVID-19 tests. This concentration points to a highly specialized or single-service operation on the Medicare side rather than a diversified clinical laboratory billing mix.
Medicaid revenue for US SPA CORP is much smaller than Medicare: total Medicaid revenue is $384.3K versus $20.4M in Medicare, indicating the provider operates at effectively single-payer scale with Medicare dominating overall revenue. The Medicaid portfolio is present but represents only a small fraction of the provider’s lifetime revenue.
Within Medicaid the provider’s revenue is concentrated but somewhat more diversified than Medicare: the top three Medicaid codes (U0003, 87811, U0005) together account for 84.7% of total Medicaid revenue, with U0003 ($165.4K, 42.8% share) and 87811 ($105.3K, 27.3% share) as the largest contributors. Those codes are all SARS‑CoV‑2 test-related, supporting a consistent COVID-19 testing service line across payers.
US SPA CORP’s national competitive standing for K1034 on Medicare is exceptional: it ranks #17 of 30,143 providers (100th percentile) and is described as an extreme outlier, which signals extraordinarily high Medicare claim volume for that single self-administered COVID‑19 test code compared with peers. This suggests the provider is a major national supplier for that specific test modality.
By contrast, the provider’s Medicaid ranks for its top codes are typical within Illinois: U0003 ranks #100 of 350 (72nd percentile), 87811 ranks #36 of 548 (94th percentile), and U0005 ranks #68 of 210 (68th percentile), each described as typical or unremarkable volume. These in-state percentiles indicate US SPA CORP is a competent, not dominant, participant in Medicaid COVID‑19 testing markets.
The code mix and descriptions (K1034, U0003, U0005, 87811, G2023) collectively indicate US SPA CORP functions primarily as a COVID‑19 testing provider handling nonprescription self-collected tests, high-throughput NAATs, and immunoassay analyses, plus specimen collection. This operational profile points to a lab or testing-distribution model rather than a broad clinical laboratory offering a wide panel of diagnostic services.
US SPA CORP was enumerated on 2021-11-03 (~5 years ago), indicating a relatively recent NPI registration consistent with a business established or reoriented during the COVID‑19 testing era. The tenure aligns with the observed service-line focus on pandemic-era SARS‑CoV‑2 testing codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,737,930 | $10 | $20.9M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 6 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,240 | $70 | $165.4K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 2,570 | $40 | $105.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,260 | $30 | $56.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,420 | $20 | $55.6K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3,540 | $1 | $3.5K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 100 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 68 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 85 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 36 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 9 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Us Spa Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Intelliride, LLC | IL | Transportation Broker | $0 | $297.1M |
| United Seating And Mobility LLC | IL | Durable Medical Equipment & Medical Supplies | $0 | $28.7M |
| Health Resources Solutions Inc | IL | Home Health Agency | $0 | $21.8M |
| U & F Sons, Inc. | IL | Homemaker | $0 | $15.6M |
| Us Medical Labs Inc | IL | Clinical Medical Laboratory | $603.4K | $12.5M |
| Mmm Diagnostic Center Inc | IL | Clinical Medical Laboratory | $939.6K | $10.9M |
| United Eg LLC | IL | Clinical Medical Laboratory | $227.3K | $11.1M |
| Kevin Mccune | IL | Family Medicine Physician | $0 | $9.6M |
| Village Of Lombard | IL | Land Ambulance | $552.9K | $6.7M |
| Cranial Technologies Inc | IL | Prosthetic/Orthotic Supplier | $0 | $5M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.